美聯新材(300586.SZ):營新科技年產2.8萬噸原甲酸酯系列產品項目已完成建設並順利投產
格隆匯 12 月 21日丨美聯新材(300586.SZ)公佈,公司於近日收到參股公司營口營新化工科技有限公司(“營新科技”)通知,營新科技年產28000噸原甲酸酯系列產品項目已完成建設並順利投產。
營新科技此次項目投產的產品為原甲酸酯系列產品,預計達產年份年產28000噸,該系列產品可在醫藥、農藥等領域廣泛運用。該項目的投產對提升營新科技盈利能力和促進其良好發展具有重大意義,同時,也進一步完善了公司在精細化工產業鏈條的戰略佈局,對公司業務結構的優化及經營業績的改善具有積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.